TinyGems

Frontieras North America Inc. Unlocks Value in America’s Energy Future

InvestorBrandNetwork (IBN) — Fri, 10 Apr 2026 15:20:00 +0000

Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy products.
Central to this strategy is the company’s patented FASForm(TM) Solid Carbon Fractionation process.
The company has not only developed its technology but is moving toward commercialization.

Frontieras North America is emerging as a noteworthy innovator and attractive potential investment opportunity by addressing one of the most critical challenges facing modern technology: the rapidly growing demand for reliable, affordable electricity.

As artificial intelligence (“AI”) and data-intensive computing expand, global electricity demand is projected to soar, with some analysts estimating AI-related power needs could grow by as much as 8,000% by the 2030s. While the rest of the industry races to meet this surging demand, Frontieras has…

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

InvestorBrandNetwork (IBN) — Fri, 10 Apr 2026 13:50:00 +0000

LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers
The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential
These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment

LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical innovation and next-generation radiotherapy (ibn.fm/C7Kms).

At the core of LIXTE’s pipeline is LB-100, a one-of-a-kind PP2A inhibitor created to improve the overall effectiveness of existing cancer therapies. Instead of competing directly with established treatments, the company is focused on boosting outcomes by amplifying them. This strategic approach underscores a…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Rail Vision Ltd. (NASDAQ: RVSN) Positions AI-Powered Collision Avoidance Tech as Solution to Rail Safety Mandates

InvestorBrandNetwork (IBN) — Fri, 10 Apr 2026 13:05:00 +0000

The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents.
Rail Vision’s proprietary sensor systems are designed to address key railway safety challenges by combining advanced imaging technologies with artificial intelligence and deep learning algorithms.
The company’s technology is also designed to integrate with existing rail infrastructure, providing flexibility for operators seeking to upgrade safety capabilities without requiring extensive system overhauls.

Rail-safety regulators are increasingly calling for advanced collision-avoidance systems as rail networks grow more complex, and Rail Vision’s (NASDAQ: RVSN, FSE: C80) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological response to those recommendations. Rail Vision develops vision-based detection systems designed to improve railway safety and operational performance, offering real-time obstacle detection and situational awareness that align closely with evolving safety priorities across the industry.

In recent years, the National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents, including fatal accidents involving maintenance equipment. The agency specifically recommended the adoption of collision-avoidance systems capable…

NOTE TO INVESTORS: The latest news and updates relating to RVSN are available in the company’s newsroom at https://ibn.fm/RVSN

Paid Promotional Disclosure

This article constitutes a paid promotional communication. Rail Vision has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this article, and has paid a fee for such services. Rail Vision exercises editorial control over the content of this article but does not control how, when, or to whom the information is distributed by such third party.

This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Rail Vision. Investing in Rail Vision’s securities involves significant risks, and readers are encouraged to review Rail Vision’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (“DBP”), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This article contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this article include, but are not limited to, statements regarding Rail Vision’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Forward-looking statements in this article include how rail-safety regulators are increasingly calling for advanced collision-avoidance systems as rail networks grow more complex, the continued modernization of the rail industry and the expansion of technologies that provide earlier detection, enhanced visibility and intelligent analysis for the railway industry. Forward-looking statements are not historical facts, and are based upon Rail Vision’s management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that Rail Vision’s management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting Rail Vision, reference is made to Rail Vision’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Rail Vision’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026. Forward-looking statements speak only as of the date the statements are made. Rail Vision assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If Rail Vision does update one or more forward-looking statements, no inference should be drawn that Rail Vision will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this article. Rail Vision is not responsible for the contents of third-party websites.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

InvestorBrandNetwork (IBN) — Thu, 09 Apr 2026 14:35:00 +0000

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments
The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials
These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies

Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its lead candidate, LB-100, at the nucleus of its strategy.

Recent updates underscore Lixte’s growing momentum as it has continued to advance LB-100, a first-in-class small molecule designed to improve the efficacy of chemotherapy, radiation, and immunotherapy while cutting down toxicity. This approach addresses one of the most pressing challenges in…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Block Co-Founder Foresees AI Doing Middle Management Tasks

InvestorBrandNetwork (IBN) — Wed, 08 Apr 2026 14:05:00 +0000

Jack Dorsey is making a concrete bet that artificial intelligence can replace what middle managers have done in large organizations for generations. Block’s chief executive, writing jointly with lead independent director Roelof Botha, has outlined a structural transformation in which AI takes on work currently handled by layers of human management.

If it holds at scale, the implications would reach well beyond Block. Given that the company has already restructured thousands of jobs around this premise, the experiment is well underway whether the theory ultimately holds or not. With more disruptive technologies like quantum computing being developed by enterprises like D-Wave Quantum Inc. (NYSE: QBTS), the employment landscape…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Wheaton Precious Metals Corp. (NYSE: WPM) (TSX: WPM) Completes $4.3B Antamina Silver Stream Deal With BHP

InvestorBrandNetwork (IBN) — Thu, 02 Apr 2026 13:45:00 +0000

Wheaton Precious Metals Corp. (WPM)This article has been disseminated on behalf of Wheaton Precious Metals Corp. and may include paid advertising.

Wheaton Precious Metals (NYSE: WPM) (TSX: WPM) announced its subsidiary Wheaton Precious Metals International Ltd. has completed a previously disclosed silver stream transaction with BHP related to the Antamina mine in Peru, securing rights to 33.75% of payable silver until 100 million ounces are delivered, followed by 22.5% for the life of mine. The agreement includes a $4.3 billion upfront payment and ongoing payments equal to 20% of the spot silver price, positioning Wheaton to enhance long-term production and cash flow through one of the world’s largest copper mines.

To view the full press release, visit https://ibn.fm/y20gR

About Wheaton Precious Metals Corp.

Wheaton Precious Metals is the world’s premier precious metals streaming company, providing shareholders with access to a high-quality portfolio of low-cost, long-life mines around the world. Through strategic streaming agreements, Wheaton partners with mining companies to secure a portion of their future precious metals production. Committed to responsible mining practices, Wheaton employs due diligence practices with a goal of unlocking long-term value for shareholders while supporting the broader mining industry to deliver the commodities society needs through access to capital. Wheaton’s shares are listed on the Toronto Stock Exchange, New York Stock Exchange and London Stock Exchange under the symbol WPM.

NOTE TO INVESTORS: The latest news and updates relating to WPM are available in the company’s newsroom at https://ibn.fm/WPM

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Researchers Solve 50-Year-Old Challenge in Making Cancer Drug

InvestorBrandNetwork (IBN) — Wed, 01 Apr 2026 14:05:00 +0000

Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more of the critical chemotherapy drug than current methods achieve. The breakthrough addresses molecular bottlenecks that forced pharmaceutical companies to rely on expensive, multi-step processes despite treating over one million cancer patients annually with the medication.

It would be interesting to hear what leading cancer drug developers like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) think about this breakthrough that has occurred half a century after doxorubicin…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Research Suggests the Thymus is Critical in Immunotherapy Outcomes

InvestorBrandNetwork (IBN) — Mon, 30 Mar 2026 14:05:00 +0000

Cancer patients with healthier thymus glands show dramatically better responses to immunotherapy, cutting progression risks by roughly one-third and death risks by nearly half compared to those with weaker thymic function. New research leveraging artificial intelligence to evaluate chest scans challenges medical assumptions that dismissed this immune organ as irrelevant past childhood, revealing it may determine who benefits from modern cancer treatments that are dependent on robust immune systems.

For businesses like Calidi Biotherapeutics Inc. (NYSE American: CLDI) engaged in the…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Reports 2025 Results, Targets Triple-Digit Growth In 2026

InvestorBrandNetwork (IBN) — Mon, 30 Mar 2026 13:15:00 +0000

Knightscope (NASDAQ: KSCP) reported full-year 2025 revenue of $11.3 million, up 5% year over year, driven by a 7% increase in service revenue to $8.0 million, while net loss widened to $33.8 million and operating expenses rose to $29.1 million. The company ended the year with $20.6 million in cash, nearly doubling from 2024, and said its recent acquisition of Event Risk positions it for expected triple-digit revenue growth in 2026 as it scales its “Hardware + Software + Humans” autonomous security platform.

To view the full press release, visit https://ibn.fm/HhM59

About Knightscope

Knightscope is a security technology company building the Nation’s First Autonomous Security Force. The Company combines autonomous machines, advanced software, and human expertise to help protect people, property, and critical infrastructure. Knightscope’s long-term mission is to make the United States of America the safest country in the world. Learn more about us at www.knightscope.com

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

InvestorBrandNetwork (IBN) — Mon, 30 Mar 2026 13:05:00 +0000

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment.
LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments.
The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study.

Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for new approaches. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is dedicated to addressing that need through the continued development of its lead compound LB-100. Recent updates from the company highlight expanding clinical trial activity designed to evaluate the drug’s potential across these difficult-to-treat cancers.

Ovarian cancer remains a serious global health concern, and the clear cell subtype presents additional treatment challenges. According to the American Cancer Society (ACS), more than 21,000 women in the United States are expected to be diagnosed with ovarian cancer this year, with an estimated…

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Partners With XTEND (NASDAQ: JFB) To Advance Autonomous Counter-Drone Systems

InvestorBrandNetwork (IBN) — Thu, 26 Mar 2026 14:35:00 +0000

ParaZero Technologies (NASDAQ: PRZO) announced a strategic partnership with XTEND (NASDAQ: JFB) to integrate its DefendAir net-launching system with XTEND’s Scorpio 1000 drone platform, enabling fully autonomous interception of hostile drones through AI-driven detection, tracking and kinetic net capture. The collaboration positions both companies to deliver advanced counter-UAS capabilities to global defense and security markets, combining high-speed maneuverability with safe interception technology designed to minimize collateral damage in complex operational environments.

To view the full press release, visit https://ibn.fm/3Tcsf

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry. Founded in 2014 by aviation professionals and drone industry veterans, ParaZero is a recognized leader in advanced drone technologies, supporting commercial, industrial, and governmental operations worldwide. The company’s product portfolio includes SafeAir, an autonomous parachute recovery system designed for aerial safety and regulatory compliance; DefendAir, a counter-UAS net-launching platform for protection against hostile drones in both battlefield and urban environments; and DropAir, a precision aerial delivery system. ParaZero’s mission is to redefine the boundaries of aerial operations with intelligent, mission-ready systems that enhance safety, scalability, and security.

NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at https://ibn.fm/PRZO

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) Reports Strong 2025 Results, Advances Growth Pipeline

InvestorBrandNetwork (IBN) — Thu, 26 Mar 2026 13:15:00 +0000

This article has been disseminated on behalf of G Mining Ventures Corp.and may include paid advertising.

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported fourth-quarter and full-year 2025 financial and operating results highlighted by 171,871 ounces of gold production at Tocantinzinho in its first full year of commercial production, $255 million in mine-site free cash flow, net income of $288 million and record fourth-quarter payable production of 47,346 ounces. Looking ahead, the company outlined a two-year outlook calling for average annual production of 200,000 ounces at Tocantinzinho, while advancing the fully funded Oko West project toward first gold in the second half of 2027 and continuing exploration and permitting work at Gurupi as it targets more than 500,000 ounces of annual gold production by 2028.

To view the full press release, visit https://ibn.fm/Y0VVY

About G Mining Ventures Corp.

G Mining Ventures Corp. is a mining company engaged in the development, operation and exploration of precious metal projects to capitalize on the value uplift from successful mine development. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored in mining-friendly jurisdictions: Brazil, with the Tocantinzinho Gold Mine and the Gurupi Project as well as Guyana, with the Oko West Project. GMIN trades on the TSX under the symbol “GMIN”.

NOTE TO INVESTORS: The latest news and updates relating to GMINF are available in the company’s newsroom at https://ibn.fm/GMINF

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Political Campaigns Start Featuring Ads Created Using AI

InvestorBrandNetwork (IBN) — Wed, 25 Mar 2026 14:05:00 +0000

Artificial intelligence has moved from a background tool into a visible presence in American political advertising and its arrival is generating real friction well ahead of the 2026 midterm cycle. Campaign teams at every level of electoral competition are finding ways to work it into their advertising, but unfortunately, it’s not always in ways that voters would recognize as synthetic.

The controversy surrounding the use of AI-generated political campaign materials highlights the potential for good and bad inherent in any new technology, and firms, such as D-Wave Quantum Inc. (NYSE: QBTS), developing cutting-edge technologies often have a limited capacity to restrict how their creations are…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

InvestorBrandNetwork (IBN) — Tue, 24 Mar 2026 13:50:00 +0000

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation
Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral exposure mattered, but how much it mattered over a patient’s lifetime. A landmark study published in The Lancet in December 2025 offered some of the clearest evidence yet, and the findings are beginning to influence how cancer treatment infrastructure is being planned.

A Survival Gap That Changes Conversation

The University of Texas MD Anderson Cancer Center led the largest randomized Phase III trial to date comparing proton therapy to traditional radiation therapy in patients with oropharyngeal cancer. The study enrolled 440 patients across 21 proton centers in the U.S. and tracked outcomes over…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Uranium Energy Corp. (NYSE American: UEC) Expands Production Capacity With Wyoming Approvals And Advances U.S. Conversion Facility Plans

InvestorBrandNetwork (IBN) — Mon, 23 Mar 2026 14:15:00 +0000

Uranium Energy (NYSE American: UEC) announced regulatory approval and startup of three additional header houses at its Christensen Ranch project in Wyoming, supporting increased uranium production capacity, while additional infrastructure remains under construction and pending approval, and its Burke Hollow project in Texas awaits final startup authorization. The company also reported that its subsidiary, United States Uranium Refining & Conversion Corp., received a docket number from the U.S. Nuclear Regulatory Commission for a planned uranium conversion facility, marking a key step in the licensing process as UEC advances its strategy to become a vertically integrated U.S. nuclear fuel supplier.

To view the full press release, visit https://ibn.fm/p1QFW

About Uranium Energy Corp

Uranium Energy Corp is America’s largest and fastest growing supplier of uranium needed to produce safe, clean, reliable nuclear energy. The Company is advancing the next generation of low-cost, environmentally friendly In-Situ Recovery (“ISR”) mining uranium projects in the United States and high-grade conventional projects in Canada. The Company has three hub and spoke platforms in South Texas and Wyoming with a combined licensed production capacity of 12.1 million pounds U3O8 per year. These production platforms are anchored by licensed Central Processing Plants (“CPPs”) and served by multiple U.S. ISR uranium projects. In August 2024, ISR operations began at the Christensen Ranch project in Wyoming, sending uranium loaded resin to the Irigaray CPP in Wyoming. The Company has diversified uranium holdings including: (1) a conventional pipeline of high-grade Canadian projects anchored by the worldclass Roughrider project; (2) one of the largest physical uranium portfolios of U.S. warehoused U3O8; and (3) a major equity stake in Uranium Royalty Corp., the only royalty company in the sector. The Company’s operations are managed by professionals with decades of hands-on nuclear fuel industry experience including the key facets of uranium exploration, development, mining and production.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Fewer Men Undergo Cancer Screening, Study Shows

InvestorBrandNetwork (IBN) — Mon, 23 Mar 2026 14:05:00 +0000

Men make up just 5% of people getting genetic tests for inherited cancer risks despite dying from cancer at higher rates than women, new research shows. Analysis of more than 224,000 tests revealed men who do get screened face much higher odds of carrying dangerous genetic mutations, with positive results hitting 14% versus 8% for women.

As entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) hit their milestones in efforts to commercialize novel therapies indicated for various malignancies, it would be of…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

InvestorBrandNetwork (IBN) — Fri, 20 Mar 2026 13:50:00 +0000

Recent research shows how chemotherapy and immunotherapy can complement each other when used together.
Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments.
Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells.

Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is working within this emerging field through the development of its experimental compound LB-100, which is designed to enhance the effectiveness of existing cancer therapies by targeting biological mechanisms that influence immune recognition and tumor sensitivity to treatment.

Interest in combining therapies stems from the reality that many cancers do not respond adequately to immunotherapy alone. Immune checkpoint inhibitors, which block proteins such as PD-1 or PD-L1 to enable immune cells to attack tumors, have transformed treatment for certain cancers but still leave…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Scientists Discover Why Colon Cancer Diagnoses are Increasing in Young Adults

InvestorBrandNetwork (IBN) — Wed, 18 Mar 2026 14:05:00 +0000

Researchers have found that people under 50 who develop colorectal cancer have unusually rigid colon tissue that helps tumors grow, offering the first clear explanation for rising cancer rates in younger adults. A University of Texas at Dallas team working with UT Southwestern Medical Center discovered that both tumor samples and surrounding healthy tissue were mechanically stiffer in younger patients than in older people with the same disease.

Understanding the conditions that drive cancer goes a long way in helping to develop therapies that attack the disease where it matters the most. With entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) also undertaking their…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update

InvestorBrandNetwork (IBN) — Tue, 17 Mar 2026 14:35:00 +0000

Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2025, alongside a shareholder update highlighting operational, clinical and financial progress. The company reported key 2025 milestones including restored NYSE American compliance, a $16.5 million capital raise, U.S.-based drug manufacturing transition and advancement of its ONP-002 program, while outlining early 2026 progress toward Phase IIa trial initiation in Australia and strategic priorities focused on patient enrollment, U.S. regulatory advancement and expansion of its CNS pipeline.

To view the full press release, visit https://ibn.fm/Dg7JA

About Oragenics, Inc.

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The Company is working on advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002 , with U.S. Phase 2b trials planned to follow. The Company’s intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit oragenics.com.

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

US Military Admits it is Using AI in Attacks Against Iran

InvestorBrandNetwork (IBN) — Mon, 16 Mar 2026 14:05:00 +0000

The U.S. military has confirmed that AI systems are actively involved in its ongoing operations against Iran, an admission that has added significant fuel to an international debate that was already running hot.

Brad Cooper, commander of U.S. Central Command, outlined the role of artificial intelligence systems in a publicly released video. He positioned AI as critical infrastructure for processing the enormous volumes of information that flow through a modern military campaign.

Other tech companies like D-Wave Quantum Inc. (NYSE: QBTS), focused on developing cutting-edge technology solutions, will be…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Receives Counter-UAS Order from Israeli Defense Entity

InvestorBrandNetwork (IBN) — Fri, 13 Mar 2026 13:55:00 +0000

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company developing autonomous solutions for the global manned and unmanned aerial systems industry, announced it has received a new purchase order from an Israeli defense entity for its DefendAir counter-unmanned aerial systems platform. The order includes delivery of an evaluation kit featuring DefendAir net pods along with live exercises and training intended to support rapid operational deployment and readiness. The DefendAir system uses patented non-explosive net-launcher technology designed to neutralize hostile drones while minimizing collateral impact and addressing evolving aerial threats across urban and battlefield environments.

To view the full press release, visit https://ibn.fm/kkAbS

About ParaZero Technologies

NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at https://ibn.fm/PRZO

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

InvestorBrandNetwork (IBN) — Fri, 13 Mar 2026 13:05:00 +0000

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK
The company operates at the nexus of targeted cancer biology and combination therapy innovation
These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100

LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100 in combination with dostarlimab for the treatment of ovarian clear cell carcinoma (https://nnw.fm/xi8sP).

The trial, initiated in January 2024, has met its initial enrolment target of 21 patients and is expected to grow to 42 participants. Results from the first cohort are projected to be out within the first half of 2026. The company’s decision to increase enrollment indicates institutional confidence in both…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Researchers Trace Differing Pediatric Brain Tumors to Common Source

InvestorBrandNetwork (IBN) — Wed, 11 Mar 2026 14:05:00 +0000

New research has uncovered a shared biological weakness running across three distinct pediatric brain cancers, a finding that opens a realistic path toward therapies capable of targeting all three at once. The discovery grew out of a deep dive into one of the rarest childhood tumors on record and ended up revealing far more than anyone initially set out to find.

As more insights are accumulated about the origins of malignancies in the brain, the future work of drug development companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) focused on bringing to…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion

InvestorBrandNetwork (IBN) — Wed, 11 Mar 2026 13:35:00 +0000

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated mechanisms, clear development pathways and strong commercial potential, while preparing legacy assets TPI 287 and berubicin for potential out-licensing to focus resources on advancing a new acquisition-driven pipeline.

To view the full press release, visit https://ibn.fm/MutVR

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The Company’s drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents TONMYA Data at International Fibromyalgia Congress

InvestorBrandNetwork (IBN) — Tue, 10 Mar 2026 13:25:00 +0000

Tonix Pharmaceuticals (NASDAQ: TNXP) announced two oral presentations on TONMYA(TM), investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. Post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies highlighted rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia, including statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15 years, was generally well tolerated, with mild and transient oral cavity reactions reported as the most common adverse events.

To view the full press release, visit https://ibn.fm/hv3Cl

Tonix Pharmaceuticals Holding Corp.*

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Ongoing Digital Monitoring Could Make Immunotherapy More Accessible

InvestorBrandNetwork (IBN) — Mon, 09 Mar 2026 14:05:00 +0000

Ongoing digital monitoring could be about to solve one of modern medicine’s most frustrating access problems. Life-extending cancer immunotherapies exist and there are numerous patients who could benefit from such therapies, but a mandatory hospital stay requirement currently makes access to immunotherapy nigh impossible for rural and underserved patients.

As more patients access these transformational treatments, many more firms would be encouraged to join the ranks of entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) seeking to…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline

InvestorBrandNetwork (IBN) — Fri, 06 Mar 2026 20:16:16 +0000

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move.

“The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors,” said Professor Steve Myers, the former Director of Accelerators and Technology at CERN. “In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. “

To view the full article, visit https://ibn.fm/W6gD5

About LIXTE Biotechnology Holdings Inc.

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

GridAI Technologies Corp. (NASDAQ: GRDX) Is Capitalizing on the Data Center and AI-Driven Transformation of the Energy Sector

InvestorBrandNetwork (IBN) — Fri, 06 Mar 2026 16:20:00 +0000

AI data centers are rapidly increasing electricity consumption, creating new and significant pressures on America’s power infrastructure, with analysts warning that reliable electricity supply could become a defining constraint in global AI competition.
Large AI facilities require integrated control of multiple energy assets and market inputs, with real-time monitoring and analytics becoming essential to the management of complex energy systems supporting AI infrastructure.
GridAI is developing software to coordinate grid power, on-site generation, battery storage and backup systems for AI data-center campuses.

Artificial intelligence has triggered a global race for computing capacity, but a serious bottleneck is beginning to emerge: electricity. For companies building and operating AI infrastructure, access to reliable power is becoming as critical as access to advanced semiconductors. That shift is creating opportunities for GridAI Technologies (NASDAQ: GRDX), a technology company focused on intelligent energy orchestration.

GridAI is advancing a real-time software platform designed to orchestrate power systems serving hyperscale AI data-center campuses. The platform coordinates multiple energy inputs, covering grid electricity, on-site generation, battery energy storage systems and backup infrastructure, while also…

NOTE TO INVESTORS: The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

InvestorBrandNetwork (IBN) — Fri, 06 Mar 2026 14:50:00 +0000

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells
LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents
The company is advancing LB-100 through clinical development in collaboration with academic and research institutions

Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to the immune system. Researchers are increasingly focused on strategies that make tumors more visible and susceptible to immune attack, and LIXTE Biotechnology Holdings (NASDAQ: LIXT) is developing a compound designed to contribute to that effort. Its lead candidate, LB-100, targets a cellular enzyme involved in tumor biology and immune regulation, with the goal of enhancing responsiveness to existing cancer therapies.

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells. Drugs targeting immune checkpoints such as PD-1 and PD-L1 have delivered durable responses in melanoma, lung cancer and other malignancies. According to the National Cancer Institute, immune checkpoint inhibitors work by blocking proteins that prevent T cells from attacking…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Reports Indicate US Military Used Anthropic’s AI in Iran Strikes

InvestorBrandNetwork (IBN) — Wed, 04 Mar 2026 14:05:00 +0000

Reports indicate the U.S. military wasstill running Anthropic’s AI models during strikes on Iran even after President Trump had formally ordered all federal agencies to stop using models developed by Anthropic.

Trailblazers like D-Wave Quantum Inc. (NYSE: QBTS) in the tech field will be watching the goings-on between the Pentagon and AI firms to learn the nuances entailed in obtaining large government…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Approved to Transfer Listing to Nasdaq Global Select Market

InvestorBrandNetwork (IBN) — Tue, 03 Mar 2026 15:15:00 +0000

Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher tier expected to begin at the open of market on March 3, 2026, under the existing ticker symbol “TNXP.” The move reflects the company’s compliance with the Nasdaq Global Select Market’s more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on growth and shareholder value creation.

To view the full press release, visit https://ibn.fm/uDmmW

Tonix Pharmaceuticals Holding Corp.

Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

InvestorBrandNetwork (IBN) — Mon, 02 Mar 2026 14:50:00 +0000

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals and Senseonics, and held senior leadership roles at Boston Scientific and Becton Dickinson. The Company said Dr. Kelley’s expertise in advancing clinical programs and executing regulatory strategy will support pipeline prioritization and long-term growth initiatives.

To view the full press release, visit https://ibn.fm/T52Ad

About CNS Pharmaceuticals, Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

New Study Unveils Promising Way to Conduct Brain Surgery Against Cancer

InvestorBrandNetwork (IBN) — Mon, 02 Mar 2026 14:05:00 +0000

A new study may have just given brain surgeons a significantly better way to fight cancer without compromising how patients live afterward. Published in Science Advances, the research unlocks a layer of information already sitting in the operating room, one that surgeons have never had the tools to interpret until now.

Once surgery is successfully completed using this brain mapping approach, medications like those being developed by pharmaceutical companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) can then…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Rail Vision Ltd. (NASDAQ: RVSN) Strengthens Commercial Momentum with Next Phase of Israel Railways Collaboration

InvestorBrandNetwork (IBN) — Fri, 27 Feb 2026 14:05:00 +0000

Rail Vision, Israel Railways outline next stage of ongoing relationship.
The ShuntingYard system is engineered for rail-yard environments, which present unique operational challenges compared with mainline operations.
The collaboration with Israel Railways will allow both parties to evaluate the technology under real-world operating conditions.

As rail operators worldwide increasingly adopt advanced technologies to improve safety, efficiency and automation, real-world pilot programs are becoming an important pathway for validating new solutions under operational conditions. Reflecting this trend, Rail Vision (NASDAQ: RVSN) announced that it is advancing its strategic collaboration with Israel Railways through a new evaluation phase focused on deploying its ShuntingYard system within the national operator’s cargo division.

The announcement outlines the next stage in an ongoing relationship between Rail Vision and Israel Railways, building on prior installations of the company’s MainLine systems on locomotives operating within Israel’s national rail network. With that earlier deployment already in place, the two…

NOTE TO INVESTORS: The latest news and updates relating to RVSN are available in the company’s newsroom at https://ibn.fm/RVSN

Paid Promotional Disclosure

This press release constitutes a paid promotional communication. Rail Vision has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this press release, and has paid a fee for such services. Rail Vision exercises editorial control over the content of this press release but does not control how, when, or to whom the information is distributed by such third party.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Rail Vision. Investing in Rail Vision’s securities involves significant risks, and readers are encouraged to review Rail Vision’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands Orbital Satcom Into Five Latin American Markets via Mercado Libre

InvestorBrandNetwork (IBN) — Thu, 26 Feb 2026 14:25:00 +0000

NextPlat (NASDAQ: NXPL, NXPLW) announced a major expansion of its Orbital Satcom North American operations into five South American markets through the launch of online storefronts on Mercado Libre, the largest e-commerce platform in Latin America. The new sites will serve customers in Mexico, Brazil, Argentina, Chile and Colombia, offering wireless and satellite-based connectivity products operating on commercial satellite networks including Globalstar, Iridium and Inmarsat. The company said the expansion targets growing regional demand for satellite-enabled voice, data, tracking and safety solutions across South America’s approximately 440 million residents, with additional market launches planned in the second quarter of 2026.

To view the full press release, visit: https://ibn.fm/68hEj

About NextPlat Corp.

NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Engineered Nanoparticles Hold Promise in Delivering Precision Cancer Treatments

InvestorBrandNetwork (IBN) — Wed, 25 Feb 2026 14:05:00 +0000

McGill University researchers have built tiny particle carriers that can shuttle cancer drugs straight to diseased lymph nodes without touching healthy tissue, reducing toxic side effects in mice compared to conventional whole-body treatment. The method tackles cancer that has spread into the lymphatic system, a particularly tough stage that typically forces surgeons to remove affected nodes despite their essential role in coordinating immune responses throughout the body.

His group is running more animal safety tests before taking a shot at human trials. The research appeared in Proceedings of the National Academy of Sciences. It would be interesting to see whether these nanoparticles can be equipped to deliver some of the novel cancer treatments being developed by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI)…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair

InvestorBrandNetwork (IBN) — Tue, 24 Feb 2026 14:45:00 +0000

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising.

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors, where she will also serve as chair of the company’s Scientific Advisory Committee, subject to approval by Cboe Canada. Dr. Lewis-Hall brings more than 40 years of experience across clinical care, research, academia and senior biopharmaceutical leadership, including more than a decade on Pfizer’s executive leadership team as executive vice president and chief medical officer, as well as leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation and Eli Lilly and Company. A Distinguished Fellow of the American Psychiatric Association and former advisor to the National Institute of Mental Health, she will provide scientific, clinical and regulatory governance across Helus’ portfolio as the company advances its novel serotonergic agonist programs targeting serious mental health conditions.

To view the full press release, visit https://ibn.fm/fcqsQ

About Helus Pharma

Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019 (the “Company”), is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.

NOTE TO INVESTORS: The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Majority-Owned Quantum Transportation Deploys Transformer-Based Neural Decoder on AWS Cloud

InvestorBrandNetwork (IBN) — Tue, 24 Feb 2026 14:34:28 +0000

Rail Vision (NASDAQ: RVSN) announced that its majority-owned subsidiary, Quantum Transportation Ltd., successfully implemented its transformer-based neural decoder on the AWS cloud, marking a milestone toward real-world quantum applications in the transportation sector. The deployment follows the recent unveiling of Quantum Transportation’s transformer neural decoder, which outperformed classical quantum error correction algorithms in simulations, and the delivery of its first universal error correction prototype, providing scalable infrastructure to process complex quantum data. The company indicated that the cloud-based implementation enables collaboration with quantum hardware partners and supports direct testing of its code-agnostic decoder on physical quantum systems, with potential long-term applications in railway anomaly detection, predictive maintenance and autonomous operations. Rail Vision completed its acquisition of a 51% stake in Quantum Transportation on Jan. 14, 2026, through a share exchange transaction.

To view the full press release, visit https://ibn.fm/2WtHh

About Rail Vision Ltd.

Rail Vision is a development stage technology company that is seeking to revolutionize railway safety and the data-related market. The company has developed cutting edge, artificial intelligence based, industry-leading technology specifically designed for railways. The company has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operators. Rail Vision believes that its technology will significantly increase railway safety around the world, while creating significant benefits and adding value to everyone who relies on the train ecosystem: from passengers using trains for transportation to companies that use railways to deliver goods and services. In addition, the company believes that its technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality. 

NOTE TO INVESTORS: The latest news and updates relating to RVSN are available in the company’s newsroom at http://ibn.fm/RVSN

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

InvestorBrandNetwork (IBN) — Mon, 23 Feb 2026 14:05:00 +0000

LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment
Liora works at the forefront of electronically controlled proton beam innovation, with its platform installed at the UK’s STFC Daresbury Laboratory
These updates highlight LIXTE’s overarching mission to blend breakthrough drug development with transformative radiotherapy innovations in the global cancer fight

Cancer is still one of the most widespread life-threatening diseases globally, with nearly all families affected either directly or as caregivers. Innovations in the medical ecosystem continue to gain momentum with the emergence of new immunotherapies, targeted drugs, and advanced radiation treatments. In light of this, LIXTE Biotech (NASDAQ: LIXT) is complementing traditional drug development into the rapidly evolving field of proton therapy, utilizing Liora Technologies, its newly acquired subsidiary (ibn.fm/UihRx).

Towards the end of 2025, the company finalized its acquisition of Liora, signaling its foray into the radiotherapy segment of cancer care. This strategic move includes Liora’s LiGHT system, which stands for Linac for Image Guided Hadron Therapy. This platform is designed to enhance the delivery of…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Canadian Defense Strategy Categorizes Quantum Computing as a High-Value Sector

InvestorBrandNetwork (IBN) — Mon, 23 Feb 2026 14:05:00 +0000

Ottawa’s latest defense industrial roadmap treats quantum computing as a strategic priority requiring government protection and accelerated development. Quantum sits alongside artificial intelligence, critical minerals, munitions, and space technologies as sectors vital for military capability and economic security.

American quantum computing firms, such as D-Wave Quantum Inc. (NYSE: QBTS), and others based in other countries will now have more concentrated competition coming from Canada in the years to…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Poised at Convergence of Electrification, EV Growth and AI Demand

InvestorBrandNetwork (IBN) — Fri, 20 Feb 2026 19:45:18 +0000

GridAI Technologies (NASDAQ: GRDX), a company operating at the intersection of artificial intelligence and energy infrastructure, is positioned for opportunity as the power grid has become a central battleground for the next phase of AI growth. An article discussing this reads, “The company is developing grid and power-management software aimed at hyperscale AI data center campuses. Its core proposition is that the limiting factor for AI infrastructure is no longer only compute capacity, but the ability to control and optimize energy at scale… This challenge is structural. Modern grids were designed for predictable demand patterns and centralized generation. AI data centers do not conform to that model. They operate continuously, draw large and variable loads, and increasingly cluster in regions where grid capacity is already strained. At the same time, electric vehicles, electrification of industry, and distributed energy resources are adding new layers of volatility… Rather than building power plants or transmission lines, the company focuses on orchestration software that allows existing assets to operate more flexibly. Its systems coordinate energy flows between grid connections, on-site generation such as reciprocating engines, battery energy storage systems (‘BESS’), and, in some cases, renewable inputs like solar.”

To view the full article, visit https://ibn.fm/QhL65

About GridAI Technologies Corp.

GridAI Technologies is a publicly listed, diversified technology and life sciences company on the Nasdaq. The company is advancing opportunities at the intersection of artificial intelligence and energy infrastructure following its acquisition of Grid AI, Inc. In addition to its GridAI operations, the company (formerly Entero Therapeutics Inc.) continues to advance its late clinical-stage biopharmaceutical program focused on the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases.

NOTE TO INVESTORS: The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

InvestorBrandNetwork (IBN) — Wed, 18 Feb 2026 14:50:00 +0000

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand.

A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard oncology regimens, but to make established modalities work better by reducing tumor resilience under treatment pressure.

What makes the current setup more distinctive is that LIXTE also owns a hardware platform. In November 2025, LIXTE announced the acquisition of Liora Technologies Europe Ltd., making it a wholly owned subsidiary. Liora’s LiGHT system, short for Linac for Image Guided Hadron Therapy, equips a proton…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Pressure from Brain Tumors Triggers Self-Destruct Mechanism in Neurons, Study Finds

InvestorBrandNetwork (IBN) — Wed, 18 Feb 2026 14:05:00 +0000

Brain tumors may damage surrounding tissue in a more insidious way than previously understood. New research from the University of Notre Dame shows that chronic pressure from an expanding tumor does not simply crush nearby neurons. It activates an internal self-destruction program that pushes those cells toward death.

With advancements being recorded by companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) in their efforts to develop novel…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team

InvestorBrandNetwork (IBN) — Tue, 17 Feb 2026 15:20:00 +0000

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers.

To view the full press release, visit https://ibn.fm/lcSDZ

About CNS Pharmaceuticals, Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Existing Cancer Drug Shows Potential in Reactivating Immunotherapy

InvestorBrandNetwork (IBN) — Tue, 17 Feb 2026 14:05:00 +0000

An already approved cancer drug called Carfilzomib may help restore the effectiveness of CAR-T cell therapy in advanced multiple myeloma cases. Technical University of Munich researchers have discovered a molecular mechanism that causes cancer cells to evade treatment and have shown that blocking it can make immunotherapy work again in some patients.

These findings offer hope that the use of CAR-T treatments could be broadened, and it comes at a time when many enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also investing heavily in developing novel…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Agrees to Acquire Majority Interest in Veloce Media Group

InvestorBrandNetwork (IBN) — Fri, 13 Feb 2026 19:35:00 +0000

SEGG Media (NASDAQ: SEGG, LTRYW) announced it has agreed to binding terms to acquire at least a majority interest in Veloce Media Group, valuing Veloce at approximately $61 million (£45 million), with closing expected Feb. 17, 2026. The transaction, to be completed through a combination of cash and SEGG common shares priced at $10 per share, is projected to contribute more than $20 million in additional annual revenue beginning in the first quarter of 2026 and will provide SEGG with a controlling interest for consolidation purposes, as the company positions the acquisition as a foundational step in building a diversified global sports, gaming and digital media platform.

To view the full press release, visit https://ibn.fm/W6hyv

About SEGG Media Corporation

SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at http://ibn.fm/SEGG

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

InvestorBrandNetwork (IBN) — Fri, 13 Feb 2026 14:50:00 +0000

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100
Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit
These two announcements paint a picture of a company advancing on multiple fronts

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its involvement in community health initiatives through its sponsorship of the Good Health: Mind, Body & Soul Summit.

Last week, LIXTE outlined advances in its approach to cancer therapy through its proprietary compound LB-100, which works by inhibiting Protein Phosphatase 2a (“PP2A”), an enzyme involved in cell growth regulation, DNA repair and immune modulation. The company described this mechanism as a…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Schedules 2025 Financial Results Conference Call for Feb. 27

InvestorBrandNetwork (IBN) — Thu, 12 Feb 2026 14:05:00 +0000

This article has been disseminated on behalf of Energy Fuels Inc. and may include paid advertising.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) a U.S.-based uranium and rare earth elements producer, will host a conference call and webcast on Friday, Feb. 27, 2026, at 9 a.m. Mountain Time to discuss its financial results for 2025. Management will lead the session followed by a question-and-answer period, with financial results and additional highlights to be issued in a press release prior to the call.

To view the full press release, visit https://ibn.fm/1LLNc

About Energy Fuels

Energy Fuels is a leading US-based critical minerals company, focused on uranium, rare earth elements, heavy mineral sands, vanadium and medical isotopes. Energy Fuels, which owns and operates several conventional and in-situ recovery uranium projects in the western United States, has been the leading U.S. producer of natural uranium concentrate for the past several years, which is sold to nuclear utilities that process it further for the production of carbon-free nuclear energy. Energy Fuels also owns the White Mesa Mill in Utah, which is the only fully licensed and operating conventional uranium processing facility in the United States. At the Mill, Energy Fuels also produces advanced rare earth element products, vanadium oxide (when market conditions warrant), and is evaluating the potential recovery of certain medical isotopes from existing uranium process streams needed for emerging Targeted Alpha Therapy cancer treatments. Energy Fuels is also developing three additional heavy mineral sands projects: the Toliara Project in Madagascar; the Bahia Project in Brazil; and the Donald Project in Australia in which Energy Fuels has the right to earn up to a 49% interest in a joint venture with Astron Corporation Limited. Energy Fuels is based in Lakewood, Colorado, near Denver. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and its common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information on all Energy Fuels does, please visit http://www.energyfuels.com

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

New AI Model Predicts Dementia Risk, Cancer Survival and Brain Age

InvestorBrandNetwork (IBN) — Wed, 11 Feb 2026 14:05:00 +0000

Mass General Brigham researchers have developed a new AI model that can estimate brain age, assess a patient’s risk of developing dementia, and help predict survival outcomes for brain cancer using routine MRI scans. The system, created within the Harvard-affiliated health network, is designed to pull multiple clinical signals from a single brain image rather than being trained for one narrow diagnostic task.

It would be interesting to learn how such an AI model would make the therapies being developed by companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) better suited to the…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

InvestorBrandNetwork (IBN) — Mon, 09 Feb 2026 14:50:00 +0000

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system
This system provides several advantages over technologies that are currently available for treating tumors with proton therapy
The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers.

Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Investors React Positively to Meta’s Plan to Increase AI Capex

InvestorBrandNetwork (IBN) — Mon, 09 Feb 2026 14:05:00 +0000

Investors are responding positively to Meta’s decision to keep increasing artificial intelligence spending, even as fears grow that the AI boom could be inflating a bubble. While concerns about a potential bust are becoming more common, Meta’s latest earnings suggest that, for now, the market is still willing to back heavy investment, particularly when it produces clear financial results.

With Zuckerberg signaling that the company is not backing away from its strategy, the market reaction suggests investors still support investments in artificial intelligence, especially among large tech companies like Meta. The way investors are responding to Meta’s plans to increase AI capex sends positive signals to other tech firms like D-Wave Quantum Inc. (NYSE: QBTS) that are focused on…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Wheaton Precious Metals Corp. (NYSE: WPM) (TSX: WPM) Announces CEO Succession and Board Leadership Transition

InvestorBrandNetwork (IBN) — Fri, 06 Feb 2026 14:05:00 +0000

This article has been disseminated on behalf of Wheaton Precious Metals Corp. and may include paid advertising.

Wheaton Precious Metals (NYSE: WPM) (TSX: WPM) today announced a planned leadership transition as part of its long-term succession strategy, naming current President Haytham Hodaly as President and Chief Executive Officer, effective March 31, 2026. Randy Smallwood will step down as CEO after more than 15 years leading the business he co-founded and will assume the role of non-executive Chair of the Board, providing leadership continuity and alignment with the company’s long-term vision. Concurrently, George Brack will transition from Chair to Lead Independent Director. Hodaly, who joined Wheaton in 2012 and was promoted to President in 2025, will also join the Board of Directors and is expected to guide the next phase of growth, building on a track record that includes executing more than $11 billion in streaming transactions and strengthening the company’s technical and capital markets capabilities.

To view the full press release, visit https://ibn.fm/AzG5t

About Wheaton Precious Metals Corp.

NOTE TO INVESTORS: The latest news and updates relating to WPM are available in the company’s newsroom at https://ibn.fm/WPM

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Retains Lake Street Capital Markets as Buy-Side Advisor to Support Acquisition Strategy

InvestorBrandNetwork (IBN) — Thu, 05 Feb 2026 15:45:00 +0000

Knightscope (NASDAQ: KSCP) announced it has retained Lake Street Capital Markets as its exclusive buy-side financial advisor to support the company’s growth strategy through selective acquisitions of complementary businesses, technologies and capabilities. The engagement aligns with Knightscope’s long-term plan to build an integrated managed security services platform combining autonomous machines, advanced software and human operations, as the company evaluates potential transactions to strengthen its technology stack and service offerings, with no specific acquisition timetable or commitments currently in place.

To view the full press release, visit https://ibn.fm/jSZ85

About Knightscope

Knightscope is a security technology company building the Nation’s first Autonomous Security Force. The Company combines autonomous machines, advanced software, and human expertise to help protect people, property, and critical infrastructure. Knightscope’s long-term mission is to make the United States of America the safest country in the world. Learn more about us at www.knightscope.com

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Subsidiary Achieves Breakthrough in Quantum Error Correction Technology

InvestorBrandNetwork (IBN) — Thu, 05 Feb 2026 15:35:00 +0000

Rail Vision (NASDAQ: RVSN) announced that its majority owned subsidiary, Quantum Transportation Ltd., has successfully developed and validated a first-generation transformer-based neural decoder designed to advance scalable quantum error correction. The company said the code-agnostic decoder demonstrated superior accuracy and efficiency in simulations across multiple quantum error correction codes and realistic noise environments, outperforming established classical decoding methods such as minimum-weight perfect matching and union-find, while supporting Rail Vision’s longer-term strategy of leveraging quantum-AI innovations alongside its core railway safety and vision technologies.

To view the full press release, visit https://ibn.fm/fiCHL

About Rail Vision Ltd.

NOTE TO INVESTORS: The latest news and updates relating to RVSN are available in the company’s newsroom at http://ibn.fm/RVSN

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Appoints Tim Healy as Executive Chairman of Operating Subsidiary

InvestorBrandNetwork (IBN) — Wed, 04 Feb 2026 14:15:00 +0000

GridAI Technologies (NASDAQ: GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, announced the appointment of Tim Healy as executive chairman of the board of Grid AI Corp., the Company’s wholly owned operating subsidiary. Healy brings more than 20 years of experience as a founder, chief executive, board leader, and investor in energy technology and the energy transition sector, including his role as co-founder, chairman, and chief executive officer of EnerNOC, which he led from inception through its Nasdaq initial public offering and eventual acquisition by Enel, and is expected to work closely with Grid AI Corp. Chief Executive Officer Marshall Chapin to guide strategy, platform development, and capital formation.

To view the full press release, visit https://ibn.fm/x5pRk

About GridAI Technologies Corp.

GridAI Technologies Corp. (Nasdaq: GRDX) is focused on developing intelligent software and control platforms that optimize the interaction between data centers, the electric grid, on-site generation, and energy storage. Through its wholly owned subsidiary, Grid AI Corp., the Company enables hyperscalers and large energy consumers to accelerate data center deployment while improving reliability, economics, and grid integration.

NOTE TO INVESTORS: The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Scientists Discover Why Immunotherapy Frequently Fails

InvestorBrandNetwork (IBN) — Wed, 04 Feb 2026 14:05:00 +0000

Although cancer immunotherapy has transformed treatment for many patients, the promise of effective immunotherapy falls short for many patients. Scientists now believe they have identified a major reason why immunotherapy isn’t always effective.

These findings are likely to be of great interest to entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are engaged in…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Returns GoFast Brand to Brick-and-Mortar Retail in Colorado

InvestorBrandNetwork (IBN) — Tue, 03 Feb 2026 18:36:11 +0000

Golden Triangle Ventures (OTC: GTVH) (“GTV”) announced that GoFast Sports & Beverage Co. has re-entered brick-and-mortar retail with placement in more than 50 store locations across Colorado, including partners such as 7-Eleven, Jenny’s Market, Byers Sinclair, A-Z Quick Marts, and several independent retailers, marking the brand’s first major retail rollout following a comprehensive operational rebuild and representing the initial phase of a disciplined regional expansion strategy that supports broader retail growth plans.

To view the full press release, visit https://ibn.fm/Ftqxu

About GoFast Sports & Beverage Co.

GoFast Sports & Beverage Co. is a legacy energy drink brand known for its performance-driven identity and dedicated community following. The brand focuses on delivering quality energy products through retail, direct-to-consumer, and strategic distribution channels.

About Golden Triangle Ventures, Inc.

Golden Triangle Ventures (OTC: GTVH) is a diversified company developing a portfolio of high-growth businesses across construction, energy, and consumer goods. Through subsidiaries such as GoldenEra Development, GoFast Sports, Deep South Electrical Contractors, and its future Manufacturing & Logistics Division, the company operates a vertically integrated model focused on profitability, innovation, and long-term shareholder value.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

ParaZero Technologies Ltd. (NASDAQ: PRZO) Positions for Urban Counter-Drone Demand with Cyprus Deal

InvestorBrandNetwork (IBN) — Tue, 03 Feb 2026 16:20:00 +0000

ParaZero entered the Cyprus market via a reseller agreement with homeland security specialist Lella Kentonis
The firm’s counter-UAS technologies are built for complex, contested, and civilian-dense environments
These updates underscore ParaZero’s mission to create and deliver scalable, low-collateral drone mitigation as threats move into the cities from the battlefields

ParaZero Technologies (NASDAQ: PRZO) is stepping up efforts targeted at its global expansion strategy as hostile drone threats extend into urban and civilian areas. The company recently announced that a reseller arrangement had been reached with Lella Kentonis Investment Co. Limited, engaging the services of the homeland security specialist as its distributor and integrator in Cyprus. With the agreement, ParaZero now has a strategically important access to European markets where more attention is being given to airspace protection (ibn.fm/ly8kz).

As part of the terms of the agreement, Lella Kentonis is expected to distribute and integrate ParaZero’s counter-UAS product lines into Cyprus’ defense and homeland security ecosystem. The partnership underscores ParaZero’s strategy of partnering with reputable regional players to ease market access…

NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at ibn.fm/PRZO

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Reaffirms 90-Day Execution Plan and Acquisition Timeline

InvestorBrandNetwork (IBN) — Mon, 02 Feb 2026 14:34:42 +0000

SEGG Media (NASDAQ: SEGG, LTRYW) provided an update on its previously announced 90-day execution plan, reaffirming its near-term focus on completing announced acquisitions, strengthening core operations and allocating capital with discipline and accountability. The company expects to close on the acquisition of a controlling interest in Veloce Esports Limited in February, subject to customary closing conditions, complete the acquisition of Nook Holdings Limited in March and finalize the acquisition of a controlling interest in Ant Media & Productions before the end of March, positioning these transactions as cornerstone priorities designed to convert announced initiatives into completed, revenue-producing operations and support the development of a stable, scalable platform for long-term value creation.

To view the full press release, visit https://ibn.fm/3caEC

About SEGG Media Corporation

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at http://ibn.fm/SEGG

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Researchers Develop Smart Nanoparticles to Destroy Proteins That Cause Diseases

InvestorBrandNetwork (IBN) — Mon, 02 Feb 2026 14:05:00 +0000

Scientists have designed a new class of nanoparticles that can actively remove harmful proteins from the body, a step that could reshape how some of the hardest diseases are treated. Instead of blocking problematic proteins, the approach focuses on eliminating them altogether.

The team is now working to move the technology toward clinical testing and partnerships, with the broader goal of turning smart nanoparticles into adaptable therapeutic tools capable of tackling diseases once considered beyond reach. This work could add a new dimension to other efforts of firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are focused on…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data for TONMYA(TM) in Fibromyalgia at Non-Opioid Pain Summit

InvestorBrandNetwork (IBN) — Fri, 30 Jan 2026 14:15:00 +0000

Tonix Pharmaceuticals (NASDAQ: TNXP) announced the presentation of clinical data for TONMYA(TM), previously investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit held Jan. 29, 2026, in Boston. The data were drawn from RESILIENT, a 14-week Phase 3 randomized, double-blind, placebo-controlled trial involving 456 patients with fibromyalgia, in which bedtime sublingual administration of TONMYA demonstrated a statistically significant reduction in weekly average pain scores at Week 14 versus placebo (p<0.0001), along with significant improvements in sleep disturbance, fatigue, and functional outcomes. Tonix reported that TONMYA was well tolerated, with low discontinuation rates and primarily mild, self-limited adverse events, supporting its potential as a differentiated, centrally acting non-opioid treatment designed to address both pain and non-restorative sleep in fibromyalgia patients.

To view the full press release, visit https://ibn.fm/VizLh

Tonix Pharmaceuticals Holding Corp.

Tonix is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix markets FDA-approved TONMYA(TM), a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. TONMYA was investigated as TNX-102 SL. Tonix also markets two treatments for acute migraine in adults: Zembrace(R) SymTouch(R) (sumatriptan injection) and Tosymra(R) (sumatriptan nasal spray). Tonix’s development portfolio* is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a Phase 2- ready Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a Phase 2- ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Novel Therapy Helps Tumor Cells Welcome Cancer Treatment

InvestorBrandNetwork (IBN) — Wed, 28 Jan 2026 14:05:00 +0000

For years, one of the biggest frustrations in cancer care has been watching immunotherapy succeed spectacularly in some diseases while stalling almost completely in others. Solid tumors, especially those that spread aggressively, have remained stubbornly resistant, not because the immune system cannot kill them, but because it often cannot get close enough to try. New research from a U.S. academic team suggests that this long-standing barrier may be more fragile than once believed.

It would be interesting to hear what enterprises like Calidi Biotherapeutics Inc. (NASDAQ: CLDI) engaged in advancing immunotherapy think…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Files to Change Corporate Name to Sports Entertainment Gaming Global

InvestorBrandNetwork (IBN) — Tue, 27 Jan 2026 17:45:00 +0000

SEGG Media (NASDAQ: SEGG, LTRYW) announced it has filed an application with the Delaware Division of Corporations to change its corporate name from Lottery.com Inc. to Sports Entertainment Gaming Global Corporation, reflecting the Company’s evolution from a lottery-focused business to a diversified platform spanning sports, entertainment, and gaming verticals. Upon acceptance by the Delaware Secretary of State, the Company will operate as SEGG Media Corp, SEGG Media, and SEGG, with the change approved by the Board of Directors and intended to support growth initiatives centered on its domain assets, including Sports.com, Concerts.com, TicketStub.com, and Lottery.com, while current management continues to advance compliance, governance reforms, and shareholder growth following legacy issues tied to former executives.

To view the full press release, visit https://ibn.fm/pJ5ic

About SEGG Media Corporation

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at http://ibn.fm/SEGG

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

InvestorBrandNetwork (IBN) — Tue, 27 Jan 2026 15:15:00 +0000

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation.

To view the full press release, visit https://ibn.fm/pXqzi

About CNS Pharmaceuticals, Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

How Bitcoin is Already Being Impacted by Quantum Computing

InvestorBrandNetwork (IBN) — Mon, 26 Jan 2026 14:05:00 +0000

Quantum computing is already affecting the cryptocurrency industry in several notable ways, and Bitcoin is increasingly at the center of that shift as investors reassess long-term technological risk. While fully capable quantum machines remain years away, their anticipated arrival is beginning to influence market behavior today, not through broken encryption, but through changing confidence.

It would be interesting to hear what tech companies like D-Wave Quantum Inc. (NYSE: QBTS) focused on advancing quantum computing have to…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

InvestorBrandNetwork (IBN) — Thu, 22 Jan 2026 14:50:00 +0000

LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments
Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile
The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise

LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target.

LIXTE’s platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A (“PP2A”). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Highlights 2025 Advancements Driving DefendAir Counter-UAS Momentum

InvestorBrandNetwork (IBN) — Thu, 22 Jan 2026 14:20:00 +0000

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company advancing smart, autonomous solutions for the global manned and unmanned aerial systems market, highlighted key industry trends and company milestones from 2025 that advanced its DefendAir counter-UAS platform, as global drone threats intensified across military, urban security and critical infrastructure environments. The Company cited strong growth in the counter-UAS market driven by increased use of low-cost commercial drones, rising global defense spending and demand for layered, modular and non-explosive solutions, particularly in urban settings, while noting DefendAir’s progress as a multi-layered, net-based interception platform that achieved a 100% success rate in controlled trials and reinforced ParaZero’s strategic positioning amid accelerating worldwide adoption of precision drone interception technologies.

To view the full press release, visit https://ibn.fm/bm4uL

About ParaZero Technologies

NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at https://ibn.fm/PRZO

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – To Participate In DealFlow Discovery Conference

InvestorBrandNetwork (IBN) — Tue, 20 Jan 2026 16:45:00 +0000

Kairos Pharma (NYSE American: KAPA) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, N.J. The company said Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors during the event as Kairos continues advancing its clinical-stage oncology programs.

To view the full press release, visit https://ibn.fm/0CBmk

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Study Discovers Molecule of Gut Bacteria That Boosts Immunotherapy Response

InvestorBrandNetwork (IBN) — Tue, 20 Jan 2026 14:05:00 +0000

Scientists have identified a compound produced by gut bacteria that sharply improves how tumors respond to immunotherapy, offering a potential breakthrough for patients who currently see little benefit from these treatments. The discovery centers on a small molecule called Bac429, which enhanced lung cancer treatment outcomes in mice and is now being developed into a drug suitable for human trials.

It remains to be seen what other players in the immune-oncology R&D field like Calidi Biotherapeutics Inc. (NYSE American: CLDI) make of this new…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Subsidiary Achieves Quantum Error Correction Breakthrough

InvestorBrandNetwork (IBN) — Fri, 16 Jan 2026 14:15:00 +0000

Rail Vision (NASDAQ: RVSN) announced that its majority-owned subsidiary, Quantum Transportation Ltd., has achieved a technical breakthrough with the successful prototype development and validation of a first-generation transformer-based neural decoder designed to advance scalable quantum error correction. The Company said the code-agnostic solution demonstrated superior decoding accuracy and efficiency versus leading classical methods in comprehensive simulations across multiple quantum error correction codes and noise environments, supported by a completed intellectual property strategy. Management noted the milestone strengthens the strategic value of its investment in Quantum Transportation while the companies explore longer-term opportunities to apply advanced data analysis and computing methodologies alongside Rail Vision’s core railway safety technologies.

To view the full press release, visit https://ibn.fm/fHTpX

About Rail Vision Ltd.

NOTE TO INVESTORS: The latest news and updates relating to RVSN are available in the company’s newsroom at http://ibn.fm/RVSN

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Agreement to Acquire Quantum Circuits Inc., Establishing World’s Leading Quantum Computing Company

InvestorBrandNetwork (IBN) — Fri, 16 Jan 2026 14:05:00 +0000

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, and Quantum Circuits, Inc. (“Quantum Circuits”), a leading developer of error-corrected superconducting gate-model quantum computing systems, recently announced that the companies have entered into a merger agreement under which D-Wave will acquire Quantum Circuits for a purchase price of $550 million, consisting of $300 million in D-Wave common stock and $250 million in cash. By combining the world’s leading annealing quantum computing company with the world’s leading developer of error-corrected gate-model technology, D-Wave aims to dramatically accelerate the projected time to a scaled, error-corrected gate-model quantum computer alongside and complementary to its commercial annealing quantum systems.

The proposed acquisition will bring together D-Wave’s deep expertise in scalable control of superconducting processors as well as its production-grade, high availability quantum cloud platform with Quantum Circuits’ leading approach to error-corrected superconducting gate-model technology. Quantum Circuits’ dual-rail technology with built-in error detection results in higher quality qubits and dramatically lowers the physical resources required for building logical qubits. Combining these technologies is expected to facilitate an accelerated commercial gate-model product roadmap that D-Wave believes will enable it to be the first to deliver fully error-corrected, scaled gate-model quantum computing. This is also projected to significantly expand the exciting use cases addressable by commercial quantum computing. The first deliverable in the accelerated roadmap will be an initial dual-rail system, planned to be generally available in 2026.

The transaction secures D-Wave’s position as the world’s first and only dual-platform quantum computing company, building and delivering industry-leading annealing and gate model quantum computing technology to address customers’ full set of complex computational problems.

To view the full press release, visit https://ibn.fm/05ZhB

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world’s largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

About Quantum Circuits, Inc.

Quantum Circuits is founded by quantum physicists, including leading quantum expert and Yale Professor Rob Schoelkopf. The company is a leader in the development of quantum computers designed to scale. Quantum Circuits’ innovative architecture integrates high-fidelity qubits with intrinsic error detection and handling. High-fidelity error detection is a key component to reducing the number of physical qubits necessary to build a useful quantum computer, thus accelerating the timeline to fault-tolerant quantum computing and real-world applications. Quantum Circuits’ team includes pioneers in the development of superconducting quantum science and circuit quantum electrodynamics. For more information, visit www.quantumcircuits.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995, including statements relating to the acquisition (including the timing and completion thereof), as well as the combined company’s development and commercialization plans, plans to accelerate the projected time to a scaled, error-corrected gate-model quantum computer and intention to make an initial dual-rail system generally available in 2026, among others. In some cases, you can identify forward-looking statements by the following words: “believe,” “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “trend,” “believe,” “estimate,” “predict,” “project,” “potential,” “seem,” “seek,” “future,” “outlook,” “forecast,” “projection,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve significant risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

ParaZero Technologies Ltd. (NASDAQ: PRZO) Announces First Successful Demonstration of the Company’s DefendAir Platform in Europe

InvestorBrandNetwork (IBN) — Wed, 14 Jan 2026 14:05:00 +0000

ParaZero has successfully demonstrated the company’s DefendAir platform for the first time on European soil, following a distribution agreement that was recently signed with a leading Western European distributor
Around 40 senior military officers representing several NATO member states from Western Europe attended the event where ParaZero demonstrated the full capabilities of DefendAir
The live exercise showcased the platforms rapid deployment, precision targeting, interception success rate, and ability to operate well in complex environments

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company, recently completed the company’s first live DefendAir demonstration on European soil. The successful demonstration followed a recently signed distribution agreement with a leading Western European distributor.

The demonstration was attended by around 40 senior military officers from a variety of NATO member states across Western Europe. The event highlighted the full operational capabilities of the ParaZero DefendAir counter-unmanned aerial platform (“C-UAS”), as it successfully neutralized simulated…

NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at https://ibn.fm/PRZO

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Cornell Researchers Develop Particles That Can Supercharge Immunotherapy

InvestorBrandNetwork (IBN) — Wed, 14 Jan 2026 14:05:00 +0000

Cornell researchers have developed particles that can supercharge immunotherapy, offering a breakthrough approach to treating resistant cancers. The nanoparticles work in an unexpected dual capacity: they fundamentally alter hostile tumor conditions while amplifying the potency of existing immunotherapy drugs.

With other approaches by entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) leveraging oncolytic viruses to…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) Moves From Grid Intelligence Narrative to Execution Test

InvestorBrandNetwork (IBN) — Tue, 13 Jan 2026 14:55:00 +0000

GridAI Technologies (NASDAQ: GRDX) sits at a critical inflection point for the grid intelligence sector, where rising power demand, constrained infrastructure timelines, and the need for real-time coordination have pushed software-driven orchestration from concept to operational necessity. The company’s relevance no longer hinges on vision or positioning but on measurable execution, specifically the amount of electrical load it actively forecasts, coordinates, and optimizes in live environments. GridAI operates at the control layer of energy economics, where customer trust is earned through consistent performance rather than pilots or demonstrations, and where the transition from testing to dependence signals durable adoption. For investors and customers alike, the key question is no longer whether grid intelligence makes sense, but whether GridAI’s execution proves scalable, repeatable, and embedded in daily operations.

To view the full press release, visit https://ibn.fm/0NjYM

About GridAI Technologies Corp.

GridAI Technologies Corp is a publicly listed company on the Nasdaq. The Company is a diversified technology and life sciences company advancing opportunities at the intersection of artificial intelligence and energy infrastructure following its acquisition of Grid AI, Inc. In addition to its GridAI operations, the Company (formerly Entero Therapeutics Inc.) continues to advance its late clinical-stage biopharmaceutical program focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

NOTE TO INVESTORS: The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy

InvestorBrandNetwork (IBN) — Tue, 13 Jan 2026 14:45:00 +0000

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on advancing differentiated cancer therapies, announced that it has engaged IBN, a multifaceted financial news and publishing company, to support its corporate communications strategy. Through the engagement, IBN will leverage its investor-focused distribution platform, including more than 5,000 syndication outlets, newsletters, social media channels, blogs and wire services via InvestorWire, to increase awareness of LIXTE’s first-in-class approach to enhancing the effectiveness of existing chemotherapy and immunotherapy treatments, including its lead clinical candidate, LB-100, across cancers with significant unmet medical need.

To view the full press release, visit https://ibn.fm/wlINV

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.

LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https:/ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Health IT Firms Call for Clearer, More Consistent AI Rules

InvestorBrandNetwork (IBN) — Mon, 12 Jan 2026 14:05:00 +0000

Health IT firms in the U.S. are calling for clearer, more consistent AI rules as conflicting state regulations create mounting challenges for companies operating across multiple jurisdictions. Industry leaders say the fragmented approach to AI regulation threatens to slow innovation while producing unequal care standards for patients depending on their location.

Other tech firms like D-Wave Quantum Inc. (NYSE: QBTS) could also be equally concerned about the current fragmentation in AI rules from one…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Preclinical Study Suggests Combo Therapy Could Treat Glioblastoma

InvestorBrandNetwork (IBN) — Wed, 07 Jan 2026 14:05:00 +0000

University of North Carolina researchers have developed a combination treatment that shows remarkable promise against glioblastoma, an aggressive brain cancer with dismal survival rates. The therapy paired a standard chemotherapy drug with a laboratory chemical called EdU to produce unprecedented results in preclinical models.

As companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) register successes in their efforts to develop other effective treatments against glioblastoma and other central nervous system cancers, there…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

InvestorBrandNetwork (IBN) — Wed, 07 Jan 2026 14:05:00 +0000

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens.
The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations.
LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition.
Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility.
Expansion of the ovarian clear cell carcinoma trial in December 2025, with plans to double patient enrollment and present initial findings in 2026, underscores continued clinical momentum.

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and…

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

New Gene Regulator Could Revive Immune System Response in Cancer Management

InvestorBrandNetwork (IBN) — Wed, 31 Dec 2025 14:05:00 +0000

A gene regulator best known for its role in bone development is now emerging as a potential lever to restore immune responses in cancer patients who stop benefiting from immunotherapy. New findings from Taiwan suggest that blocking this regulator, RUNX2, may help worn-down immune cells regain their ability to fight tumors.

With immense human and financial resources being directed by firms like Calidi Biotherapeutics Inc. (NYSE American: CLDI) into studying how immunotherapy can be improved to help a lot more cancer patients, this study provides further proof that cancer treatment is set for a major transformation over…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces $20 Million Registered Direct Offering with Point72

InvestorBrandNetwork (IBN) — Mon, 29 Dec 2025 16:09:38 +0000

Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has entered into a securities purchase agreement with Point72 for a registered direct offering of 615,025 shares of common stock at $16.26 per share, or pre-funded warrants to purchase up to an aggregate of 615,025 shares at a purchase price of $16.259 per warrant, for gross proceeds of approximately $20.0 million before fees and expenses. The offering is expected to close on or about Dec. 30, 2025, subject to customary closing conditions, with net proceeds intended to fund commercialization of marketed products, development of the company’s product pipeline, and general working capital and corporate purposes. TD Cowen is acting as sole placement agent, with A.G.P./Alliance Global Partners serving as financial advisor.

To view the full press release, visit https://ibn.fm/Wt9Ek

Tonix Pharmaceuticals Holding Corp.

Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Al Jazeera Unveils AI Tool to Support Their Teams

InvestorBrandNetwork (IBN) — Fri, 26 Dec 2025 14:05:00 +0000

Al Jazeera is unveiling a new artificial intelligence platform aimed at supporting its teams as journalism becomes more data-heavy and faster paced. The initiative, called “The Core,” is being developed in partnership with Google Cloud and is designed to weave AI directly into the network’s daily news operations.

Corporations like Al Jazeera that are embracing AI in ways that are tailored to their specific needs could benefit the most from this new technology and get an edge over their peers. Such corporation are likely to thrive in this age when many companies like D-Wave Quantum Inc. (NYSE: QBTS) are working to bring to the mainstream even more advanced quantum computing systems. The companies that thrive are…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

New Blood Test Reveals Whether Treatment is Working for Brain Cancer Patients

InvestorBrandNetwork (IBN) — Mon, 22 Dec 2025 14:05:00 +0000

Researchers have revealed a new blood test that can determine whether brain cancer therapies are being effective. The diagnostic tool could guide glioblastoma physicians on whether to maintain current drug regimens, change medications, or halt interventions altogether. Adam Sonabend, a Northwestern Medicine neurosurgeon who co-directed a study published in Nature Communications, explained that using this test, treatment effectiveness becomes apparent after a single dose instead of months of waiting.

The eventual commercialization of this blood test could be pivotal in confirming that patients are benefiting from any novel therapies from entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) indicated for…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Novel Biomarker Could Predict Resistance to Immunotherapy, Study Finds

InvestorBrandNetwork (IBN) — Wed, 17 Dec 2025 14:05:00 +0000

Scientists at Northwestern Medicine have discovered a biological marker that predicts which cancer patients are more resistant to immunotherapy. Dubbed USP22, the marker also points to a potential treatment target for non-responders. Findings published in The Journal of Clinical Investigation have the potential to transform care for patients whose current options remain limited.

Given the pace at which enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are making progress in their research and…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

US Navy, Palantir Partner to Build AI Submarine

InvestorBrandNetwork (IBN) — Mon, 15 Dec 2025 14:05:00 +0000

The U.S. Navy has partnered with AI firm Palantir on a $448 million effort to advance computational intelligence and machine automation throughout submarine production. This partnership aims to transform shipyard workflows using sophisticated analytics and prediction tools. Maritime Industrial Base Program leaders alongside Naval Sea Systems Command will direct the Shipbuilding Operating System initiative.

This collaboration gives many other tech firms like D-Wave Quantum Inc. (NYSE: QBTS) encouragement that as their innovations prove their worth in the field, there may be no shortage of governmental and…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Optimal Treatment Timing Could Boost Cancer Therapy Efficacy

InvestorBrandNetwork (IBN) — Wed, 10 Dec 2025 14:05:00 +0000

Administering chemotherapy at specific times could significantly improve outcomes for brain cancer patients. Washington University in St. Louis researchers discovered that treatment timing plays a crucial role in how effectively glioblastoma patients respond to standard drug protocols. Funding came from NCI, Siteman Cancer Center, and National Institutes of Health, with the cancer center operating at WashU Medicine and Barnes-Jewish Hospital.

As more teams at firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) undertake R&D programs aimed at developing novel therapies against…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Study Proposes Overhaul of US Lung Cancer Screening Guidelines

InvestorBrandNetwork (IBN) — Mon, 08 Dec 2025 14:05:00 +0000

A new analysis is calling for major changes to how the United States screens for lung cancer. Current rules, the study argues, leave out most people who eventually develop the disease. Researchers behind the study say the system used today is far too narrow and fails to capture the full range of Americans who end up at risk.

Improvements in screening and catching the cancer earlier could deliver maximum therapeutic value from the treatments that companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are working to commercialize since…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

EV Expertise Fuels Successes in Chinese-Made Flying Cars

InvestorBrandNetwork (IBN) — Wed, 03 Dec 2025 14:05:00 +0000

China’s battery-car mastery is propelling its flying vehicle manufacturers ahead of global rivals. Expertise developed through years of electric vehicle production and unmanned aircraft development is giving domestic companies a distinct edge in the nascent aerial mobility market.

As electric vehicle makers like Bollinger Innovations, Inc. (OTC: BINI) master their craft, there is…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Nvidia’s Great Earnings Report Fails to Dim AI Investors’ Fears

InvestorBrandNetwork (IBN) — Wed, 26 Nov 2025 14:05:00 +0000

Nvidia’s great earnings report failed to calm the growing unease around the AI trade, and that tension shaped the mood in markets this week. The company’s blockbuster quarter reaffirmed that demand for AI hardware remains powerful, yet instead of settling the debate, it exposed how sharply divided investors have become over the long term payoff of surging AI investments.

Companies like D-Wave Quantum Inc. (NYSE: QBTS) that are focused on a…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Building Global Audience Through Live Competition: How SEGG Media Corporation (NASDAQ: SEGG) Is Scaling Sports Content and Female Motorsport Visibility

InvestorBrandNetwork (IBN) — Fri, 21 Nov 2025 15:35:00 +0000

Sports.com has surpassed 45 million cumulative live-stream views since launch, fueled by expanding motorsport coverage and global football partnerships
Driver Jorden Dolischka became the first woman ever to reach the podium in Gulf Radical Cup history
The company secured title sponsorship of Soccerex Miami 2025, placing Sports.com alongside elite clubs and global football leaders ahead of the 2026 FIFA World Cup

In an entertainment market dominated by endlessly expanding archives, a different form of content is proving more durable and harder to replicate live competition. Unlike recorded programming, live sports draw audiences at the exact moment events unfold, creating concentrated engagement windows and highly predictable monetization opportunities. For companies that can combine rights acquisition, production infrastructure, and global distribution, the economics of live streaming offer a powerful alternative to algorithm-driven platforms. SEGG Media (NASDAQ: SEGG, LTRYW) is building its strategy around that premise, expanding across motorsport, football and emerging live-event formats, where traditional broadcasters have yet to establish dominance.

Motorsport as a Scalable Proving Ground

In November of this year, Racing Women drivers Jorden Dolischka and Léna Galyó competed in Round 1 of the Gulf Radical Cup at Abu Dhabi’s Yas Marina Circuit, the same course used for Formula One’s season finale. The pair were the only female competitors in a grid of 18 racers. Both posted top 10 in…

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at https://ibn.fm/SEGG

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Study identifies Biomarker to Predict Success of Immunotherapy, Chemo for Breast Cancer

InvestorBrandNetwork (IBN) — Wed, 19 Nov 2025 14:05:00 +0000

Researchers from the University of Illinois Urbana-Champaign have discovered a protein that can predict which breast cancer patients will respond well to chemotherapy and immunotherapy. After conducting genome-wide screening in human cancer cells, the research team found that the FGD3 protein was a promising biomarker in determining chemotherapy and immunotherapy efficacy.

For companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are focused on developing new immunotherapies targeting different kinds of…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

EV Sales in China Set New Record in October

InvestorBrandNetwork (IBN) — Mon, 17 Nov 2025 14:05:00 +0000

Data from the China Association of Automobile Manufacturers (CAAM) has revealed that China sold 1.7 million electric and plug-in hybrid vehicles in October, setting a new monthly record for the rapidly expanding electric vehicle market.

American automakers like Bollinger Innovations, Inc. (OTC: BINI) have a steep climb ahead of them to record the kind of sales that…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

UK Government Announces $18.4M in Awards to Support Quantum Computing Projects

InvestorBrandNetwork (IBN) — Wed, 12 Nov 2025 14:05:00 +0000

British officials have allocated $18.4 million in awards to support over a dozen quantum computing projects. The Quantum Sensing Mission Primer awards’ goal is quite ambitious: deploy quantum computers that surpass current supercomputers by 2036. Science minister Patrick Vallance called the technology revolutionary, noting that it could transform medical diagnostics and slash computation times from decades to seconds. Cumulatively, the UK has pledged $880 million to advance quantum technology development in the country.

American firms like D-Wave Quantum Inc. (NYSE: QBTS) are racing to commercialize quantum computing innovations that…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

New Implants Defy Necessity of Brain Surgery Against Cancer

InvestorBrandNetwork (IBN) — Mon, 10 Nov 2025 14:05:00 +0000

Microscopic wireless electronics that self-navigate to diseased brain tissue could eliminate the need for surgery when treating tumors and neurological conditions. Massachusetts Institute of Technology researchers demonstrated the technology in mice, showing how tiny devices injected into the bloodstream can autonomously locate target regions and deliver electrical stimulation without human guidance.

As the researchers take these new implants through the clinical study process, companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also making notable…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) and BASF Complete Proof-of-Concept Project, Demonstrating Benchmark in Manufacturing Efficiency

InvestorBrandNetwork (IBN) — Thu, 06 Nov 2025 14:05:00 +0000

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and BASF, one of the world’s leading chemical companies, have completed a joint proof-of-concept project that used a hybrid-quantum application to optimize manufacturing workflows in a BASF liquid-filling facility. D-Wave’s hybrid-quantum technology set a new benchmark for manufacturing efficiency, allowing reduction of production scheduling time from 10 hours to just seconds, reducing lateness by 14% and setup times by 9%, and shortening tank unloading durations by up to 18%.

“This project showcases how hybrid-quantum computing can help address manufacturing and supply-chain operational bottlenecks and begin delivering measurable value where classical computing falls short,” said Dr. Alan Baratz, CEO of D-Wave. “We are thrilled to work with BASF and see these impressive, industry-defining results.”

“D-Wave’s hybrid quantum technology demonstrated in this proof-of-concept that it has the potential to significantly improve optimization tasks, delivering faster decisions and better outcomes than classical-only solutions,” said Ionel Rusu, quantum computing innovation management, BASF.

To view the full press release, visit https://ibn.fm/4ssj3

About D-Wave Quantum Inc.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements include, but are not limited to, statements regarding the redemption of the Warrants. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Cancer Immunotherapy Could Be Transformed by Boosting Natural Killer Cells

InvestorBrandNetwork (IBN) — Wed, 05 Nov 2025 14:05:00 +0000

Researchers at MIT and Harvard Medical School have developed a method to enhance natural killer cells that could transform cancer immunotherapy. The team engineered chimeric antigen receptor natural killer cells with modifications that prevent immune system rejection and improve their ability to destroy tumors. Early experiments in mice and laboratory human tissue show the enhanced cells are effective at fighting cancer and well tolerated, offering a promising foundation for next-generation treatments.

Many firms, such as Calidi Biotherapeutics Inc. (NYSE: CLDI), are also focused on…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

China Moves to End Subsidies to its EV Industry

InvestorBrandNetwork (IBN) — Mon, 03 Nov 2025 14:05:00 +0000

Beijing has removed electric vehicles from its list of strategic emerging industries for the first time in over a decade, signaling a fundamental shift in how the world’s largest automotive market will support its dominant EV sector. The exclusion of NEVs from China’s 2026-2030 five-year development plan indicates policymakers believe the industry has matured enough to compete without tens of billions’ worth of government subsidies and customer incentives.

North American EV makers like Bollinger Innovations, Inc. (OTC: BINI) will take little comfort from the phasing out of…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

AMD Shares Jump as IBM Says its Existing Chips Can Correct Quantum Computing Errors

InvestorBrandNetwork (IBN) — Wed, 29 Oct 2025 13:05:00 +0000

AMD shares surged by nearly 8% on Friday after IBM announced that standard AMD chips can run a critical quantum computing error correction algorithm. Investors’ response to the breakthrough in qubit technology advancement caused IBM stock to climb approximately 8% as well, heading toward its best single-day performance since January.

Their partnership comes at a time of intensifying competition in the nascent quantum computing industry. Google unveiled its breakthrough Willow chip last year, while Microsoft introduced its first quantum computing chip in 2024. Amazon is also investing in the technology, with Google executives suggesting that the field is approximately five years away from a major breakthrough. Major technology firms like D-Wave Quantum Inc. (NYSE: QBTS) view quantum mechanics as an essential tool for…

NOTE TO INVESTORS: The latest news and updates relating to D-Wave Quantum Inc. (NYSE: QBTS) are available in the company’s newsroom at https://ibn.fm/QBTS

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Scientists Uncover Possible Driver of ‘Chemo Brain’

InvestorBrandNetwork (IBN) — Mon, 27 Oct 2025 14:05:00 +0000

A recent study has found that the cognitive difficulties which cancer patients experience during and after treatment could stem from chemotherapy-induced damage to the brain’s waste drainage network. Newly discovered evidence sheds light on a widespread yet poorly understood phenomenon that affects up to 75% of individuals undergoing cancer therapy, chemo brain. The symptoms associated with this condition, including memory lapses and problems with concentration and finding words, typically persist long after treatment is complete.

As firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) continue their quest to…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Study Suggests mRNA Covid Vaccine Could Boost Cancer Immunotherapy

InvestorBrandNetwork (IBN) — Wed, 22 Oct 2025 14:05:00 +0000

New research published at the European Society for Medical Oncology conference on Sunday has revealed that the mRNA coronavirus vaccine could have an unintended benefit: boosting immunotherapy effectiveness.

Immune-oncology companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also engaged in the quest for more effective approaches to…

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN

TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Expiration of Final Hedge Fund Warrants and Confirms Oct. 27 CVR Record Date

InvestorBrandNetwork (IBN) — Tue, 21 Oct 2025 13:12:00 +0000

This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced the expiration at 5 p.m. ET of 53,147 warrants (originally 3,454,543 pre-reverse-split warrants) issued to hedge funds and investment funds as part of a 2020 financing, marking the final tranche of such warrants. The Company also reaffirmed Oct. 27, 2025 as the record date for the distribution of contingent value rights (“CVRs”) to Class B Subordinate Voting Shareholders on a one-for-one basis, entitling holders to a potential pro rata share of 10%–50% of any net proceeds from Quantum BioPharma’s $700 million litigation against CIBC World Markets, RBC Dominion Securities, and others.

To view the full press release, visit https://ibn.fm/g52XC

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About TinyGems

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com